Human Hepatitis B Immunoglobulin Bio Products Laboratory (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin is indicated for passive immunization against hepatitis B virus in specific exposure scenarios.

• Post‑exposure prophylaxis for individuals with known or suspected exposure to hepatitis B virus.
• Prevention of infection in newborns of mothers who are hepatitis B surface antigen positive.
• Protection of healthcare workers after occupational needlestick injuries involving hepatitis B‑positive blood.
• Use in patients undergoing liver transplantation who lack protective anti‑HBs antibodies.
• Supplementation for individuals with inadequate response to hepatitis B vaccination.

• The immunoglobulin preparation supplies exogenous anti‑hepatitis B surface (anti‑HBs) antibodies that bind to circulating hepatitis B virus particles. By neutralizing the viral envelope proteins, the antibodies prevent attachment and entry into hepatocytes, thereby interrupting the infection cascade. This passive transfer of immunity provides immediate, short‑term protection until the host can develop its own active immune response. The effect persists for several weeks in the recipient.

Adverse reactions to Human Hepatitis B Immunoglobulin are generally mild and transient, but serious immune‑mediated events have been reported.

Common

• Injection‑site pain or tenderness.
• Redness or swelling at the injection site.
• Low‑grade fever or chills.
• Headache or mild nausea.
• Fatigue or malaise.

Serious

• Anaphylaxis with respiratory distress, urticaria, or facial swelling.
• Serum‑sickness–like reaction (fever, rash, joint pain).
• Acute hemolysis or severe hypotension.

Patients should report any unexpected symptoms to a healthcare professional promptly.

Before administering Human Hepatitis B Immunoglobulin, several safety considerations should be reviewed.

• Confirm no known hypersensitivity to human immunoglobulin or any product component.
• Assess pregnancy and lactation status; benefits should outweigh potential risks.
• Evaluate for immunocompromised conditions that may alter response.
• Monitor for signs of allergic reaction during and after injection.
• Ensure appropriate timing after exposure (ideally within 14 days).
• Verify that the patient has not received another blood‑derived product within the previous 3 months.

Human Hepatitis B Immunoglobulin may interact with other agents, affecting efficacy or safety. Interactions can affect the immunoglobulin’s clearance, increase the risk of adverse events, or interfere with diagnostic testing.

Avoid

• Concurrent administration of live attenuated vaccines (e.g., measles, varicella) as immunoglobulin can reduce vaccine effectiveness.
• Simultaneous infusion of other blood products that may increase risk of volume overload.
• Administration with other immunoglobulin products within 24 hours, which may cause additive volume load.

Use with caution

• Immunosuppressive therapies (e.g., corticosteroids) that could diminish the passive antibody effect.
• Anticoagulants, because intramuscular injection may increase bleeding risk.
• Diagnostic serologic tests for hepatitis B, as passive antibodies can cause false‑positive results.
• Renal impairment, as large protein load may affect kidney function.
• Pregnancy, due to limited safety data.